Results · Healthcare & Life Sciences

Tata 1mg revenue nears Rs 3,000 Cr with narrowing loss

By Startup Enthusiast · 28 July 2026

What they do

Tata 1mg is a digital healthcare platform selling medicines and diagnostics online

FY26 revenue reached Rs 2,936 Cr while net loss narrowed to Rs 287 Cr

The company faces competition from Netmeds, PharmEasy, and Apollo 24/7 in the market

Tata 1mg reported FY26 consolidated revenue of Rs 2,936 Cr, up 23% from FY25.
The company's net loss narrowed to Rs 287 Cr for the fiscal year 2026.
Revenue split showed Rs 2,440 Cr from Healthcare Solutions and Rs 496 Cr from Technologies.
Tata 1mg Healthcare Solutions posted a loss of Rs 310 Cr during the period.
Tata 1mg Technologies contributed a profit of Rs 23 Cr to the combined results.
Total assets stood at Rs 2,268 Cr with liabilities totaling Rs 1,601 Cr.
Reserves remained negative at Rs 167 Cr due to significant losses in the healthcare entity.
Tata Digital acquired a majority stake in 1mg in June 2021 to expand its ecosystem.

Tata Digital group revenue grew 12% to Rs 35,990 Cr in FY26.
The parent group's net loss widened to Rs 4,974 Cr from the previous year.
Tata Digital GMV reached Rs 46,515 Cr indicating strong transaction volumes across sectors.

The platform sells allopathic, ayurvedic, and homeopathic medicines through its online store.
It offers vitamins, nutrition supplements, and general healthcare products to consumers.
Diagnostics services form a key part of its healthcare service offerings.
The company operates under two entities: Healthcare Solutions and Technologies.
Healthcare Solutions drives the majority of revenue and asset base.
Technologies contributes smaller revenue but remains profitable independently.
The business model relies on digital distribution of medical products.
It competes directly with other major online pharmacy players in India.